Haematologica, Vol 92, Issue 1, 143-144 doi:10.3324/haematol.10297
Copyright © 2007 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dawson, M. A.
Right arrow Articles by Spencer, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dawson, M. A.
Right arrow Articles by Spencer, A.

Multiple Myeloma

Extramedullary relapse of multiple myeloma associated with a shift in secretion from intact immunoglobulin to light chains

Mark A. Dawson*,, Sushrut Patil°, Andrew Spencer*,°

* Department of Haematology and Bone Marrow Transplantation, The Alfred Hospital, Commercial Road, Prahran, Melbourne, Victoria 3181, Australia;
° Department of Clinical Haematology, Monash Hospital, Clayton Road, Clayton, Melbourne, Victoria 3168, Australi

Correspondence: Mark A. Dawson, The Alfred, Commercial Road, Prahran, Melbourne, Victoria, Australia 3181. Phone: international +61.39.2762000. Fax: international + 61.39.2763021. E-mail: dawsonm{at}ausdoctors.net

Biological therapies in multiple myeloma have heralded a new and exciting era for treatment to combat this disease. However the evolutionary pressures that these drugs place on the microenvironment has resulted in a change in the biological behaviour of this malignancy and novel manifestations of relapsed disease. This is illustrated in our series of three patients showing fulminant relapse of disease with plasmablastic features, an extramedullary predilection and a shift in secretion from intact immunoglobulin to free light chains only.




This article has been cited by other articles:


Home page
 Ann OncolHome page
M. Varettoni, A. Corso, G. Pica, S. Mangiacavalli, C. Pascutto, and M. Lazzarino
Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients
Ann. Onc., February 1, 2010; 21(2): 325 - 330.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
K. Murata, R. J. Clark, K. S. Lockington, L. J. Tostrud, P. R. Greipp, and J. A. Katzmann
Sharply Increased Serum Free Light-Chain Concentrations after Treatment for Multiple Myeloma
Clin. Chem., January 1, 2010; 56(1): 16 - 18.
[Full Text] [PDF]

Home page
 Ann OncolHome page
A. Avigdor, S. Bulvik, I. Levi, E. J. Dann, N. Shemtov, G. Perez-Avraham, A. Shimoni, A. Nagler, I. Ben-Bassat, and A. Polliack
Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan is an effective regimen for advanced high-risk Hodgkin's lymphoma
Ann. Onc., January 1, 2010; 21(1): 126 - 132.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
T. Gernsheimer
Chronic Idiopathic Thrombocytopenic Purpura: Mechanisms of Pathogenesis
Oncologist, January 1, 2009; 14(1): 12 - 21.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
M. J. Ayliffe, F. E. Davies, D. de Castro, and G. J. Morgan
Demonstration of changes in plasma cell subsets in multiple myeloma
Haematologica, August 1, 2007; 92(8): 1135 - 1138.
[Abstract] [Full Text] [PDF]